Pharmaceutical Testing and Development
Block1 Icon

PDX Models

StemMed provides state-of-the-art pre-clinical drug testing services using a large panel of patient-derived xenograft (PDX) models of breast and pancreatic cancers. Breast cancer PDX models were developed from an ethnically diverse patient population, and represent all clinically-defined subtypes, including estrogen receptor positive (ER+), HER2+, and “triple-negative” cancers.


StemMed has extensive experience in performing in vivo drug testing assays using PDX models. All studies are custom designed to meet your experimental goals, and can range from dose-response assays in a single PDX, to full scale animal clinical trials in 20 or more PDX.


StemMed is developing C188-9, a first-in-class, oral inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3), for targeted therapy of breast cancer (including triple-negative), and other diseases. These diseases include cachexia secondary to cancer or chromic kidney disease, idiopathic pulmonary fibrosis, scleroderma, inflammatory bowel disease, asthma, and immediate-type hypersensitivity reactions.